Charles Richter King
Keine laufenden Positionen mehr
Profil
Charles Richter King was Senior Vice President of Research for GenVec, Inc. until April 15, 2009.
He joined GenVec in 1998.
Previously, he was Vice President of New Product Research for GenVec and Director of Drug Discovery for Oncologix.
Dr. King directed an experienced research group at the Georgetown University Medical School's Lombardi Cancer Research Center in Washington, DC, where he served as Associate Professor with the University's Department of Biochemistry.
He received a PhD in Biochemistry from Johns Hopkins University.
Ehemalige bekannte Positionen von Charles Richter King
| Unternehmen | Position | Ende |
|---|---|---|
| GENVEC INC | Technik-/Wissenschafts-/F&E-Leiter | 15.04.2009 |
| AGENUS INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Charles Richter King
| The Johns Hopkins University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AGENUS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |